Who we are
J.P. Morgan Life Sciences Private Capital invests in early-stage biotherapeutics and late-stage healthcare companies. We seek to work tirelessly alongside entrepreneurs to transform the future of healthcare. The intersection of biology, engineering and computation requires a team with experience across the spectrum.
What we focus on
Our experienced team built a platform to invest in early-stage biotechnology and late-stage healthcare companies.
Our team of company operators and investors are focused on Series B through pre-IPO investments within biotechnology, medical devices, tools, diagnostics, healthcare technology and pharmaceutical services.
Our expertise and J.P. Morgan's capabilities & unique stature provide a one-stop-shop for our portfolio companies.
Our team of company builders, operators and investors are focused on company creation, Seed and Series A investments across all therapeutic areas in biotechnology.
Our team
Stephen Squinto, PhD
Chief Investment Officer
Gaurav Gupta, MD, MSE
Managing Partner
Anya Schiess
Managing Partner
Joseph Siletto
Managing Partner
Claudine Prowse, PhD
Partner
David Epstein
Former CEO, Seagen
Laurie Glimcher, MD
President and CEO, Dana Farber Cancer Institute
Jeff Leiden, MD, PhD
Executive Chairman, Former CEO, Vertex Pharmaceuticals
Frederic Moll, MD
Chief Development Officer, J&J Medical Devices
Stephen Oesterle, MD
Former Senior Vice President, Medtronic
News and insights